# A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

> **NCT03231969** · PHASE2 · COMPLETED · sponsor: **Faes Farma, S.A.** · enrollment: 121 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Bilastine 0.2%
- **DRUG:** Bilastine 0.4%
- **DRUG:** Bilastine 0.6%
- **DRUG:** Bilastine 0%

## Key facts

- **NCT ID:** NCT03231969
- **Lead sponsor:** Faes Farma, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-20
- **Primary completion:** 2017-10-11
- **Final completion:** 2017-10-11
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03231969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03231969, "A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03231969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*